rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Kalaris Therapeutics, Inc.

KLRS · Nasdaq

Health CareBiotechnologyNot moving yet

KLRS stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 31 weeks. It is 57.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 31
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$12.4M
Insider sales, 12 months
$26K
Officials’ trades on record
0
Institutions holding
54 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$9.6MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months1
Buyers · sellers3 · 1
WhoDidSharesTraded
Srinivas AkkarajuDirector, 10% ownerbought244,300at $4.8320 May 2026filed 22 May 2026
Brett R. HagenChief Accounting Officersold1,915at $6.7220 Mar 2026filed 23 Mar 2026
Srinivas AkkarajuDirector, 10% ownerbought479,847at $10.4218 Dec 2025filed 17 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders54-2 on the quarter
New · exited10 · 11
Reported value$73.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SAMSARA BIOCAPITAL, LLCreduced · filed 14 Aug 202612,881,175$52.4M-66,906−0.5%
RTW INVESTMENTS, LPunchanged · filed 14 Aug 20261,300,000$5.3M00.0%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026572,687$2.3M00.0%
Siren, L.L.C.unchanged · filed 13 Aug 2026435,798$1.8M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026398,712$1.6M+143,364+56.1%
Ikarian Capital, LLCunchanged · filed 14 Aug 2026360,000$1.5M00.0%
UBS Group AGadded · filed 13 Aug 2026262,131$1.1M+255,947+4138.9%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026149,351$608K+83,200+125.8%
MARSHALL WACE, LLPadded · filed 13 Aug 2026139,201$567K+71,322+105.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026114,037$464K+26,492+30.3%
31 Mar 2025 – 30 Jun 2026
304355Mar 25Jun 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Amy O'Leary Vandekop Company insiderVP, Corporate Controller · last 27 Aug 20260 · 0
Laurie Keating Company insiderDirector · last 1 Aug 20260 · 0
Liisa Ann Bayko Company insiderChief Financial Officer · last 20 Jul 20260 · 0
Anthony P. Adamis Company insiderDirector · last 3 Jun 20260 · 0
David Hallal Company insiderDirector · last 3 Jun 20260 · 8
Leone D. Patterson Company insiderDirector · last 3 Jun 20260 · 0
Michael Dybbs Company insiderDirector · last 3 Jun 20260 · 0
Morana Jovan-Embiricos Company insiderDirector · last 3 Jun 20261 · 7
Napoleone Ferrara Company insiderDirector · last 3 Jun 20260 · 0
Srinivas Akkaraju Company insiderDirector · last 3 Jun 20262 · 0
Samsara Biocapital, L.p. Company insider10% owner · last 20 May 20261 · 0
Brett R. Hagen Company insiderChief Accounting Officer · last 20 Mar 20260 · 50

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-41.2%
Interest coverFY 2025 · to 31 Dec 2025-31.98×
Share count trendFY 2025 · to 10 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$98.1M
Free cash flowFY 2025 · to 31 Dec 2025−$38.6M

Analyst forecasts

No analyst forecasts yet.